T-cell receptor on allergen-specific CD4+ T cells (TCR)

T-cell receptors (TCRs) on allergen-specific CD4+ T cells are the primary molecular sensors that recognize specific allergenic peptides presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells (NIH, 2023). In individuals with allergic diseases, these TCRs are predominantly expressed on Th2-polarized cells, which orchestrate the allergic inflammatory cascade by secreting pro-inflammatory cytokines and promoting IgE production (PubMed, 2021). Targeting these specific TCRs is the fundamental principle of allergen-specific immunotherapy (AIT), which seeks to desensitize the immune system by inducing long-term tolerance in these pathogenic T-cell clones (StatPearls, 2023). Modern therapeutic approaches, including peptide-based vaccines and MHC-peptide complexes, are designed to interact directly with the TCR to promote T-cell anergy or the induction of regulatory T cells (Tregs) (PubMed, 2022). By focusing on the specific TCRs involved in the allergic response, these treatments offer a precision medicine approach to managing chronic allergic conditions and preventing severe reactions like anaphylaxis (PubMed, 2018). This targeted strategy aims to address the underlying cause of immune dysfunction rather than merely suppressing symptoms.

Other names

Allergen-specific T-cell receptorAntigen-specific TCRCD4+ T-cell receptorAllergen-reactive TCR

Modulation of TCR signaling through controlled antigen exposure to induce immune tolerance, anergy, or clonal deletion of pathogenic Th2 cells, often shifting the immune response toward a Th1 or regulatory T-cell (Treg) profile.